Home
overview
If you want to keep up to date with the recent developments and advances in Anti-Inflammatory Therapeutics, the easiest way is to attend SMi’s anti-inflammatory therapeutics conference. SMi’s event offers you the simple way to stay ahead of the game, by covering the latest hot topics in anti-inflammatory therapeutics.

The conference aims to show how the anti-inflammatory therapeutic future markets will be expanded by pre-clinical development, clinical trials and new applications. It will bring together leaders in the fields of anti-inflammatory clinical trials, research and development, share up to date information about the current situation surrounding this exciting field, and to analyse the future of the industry.

Why you should attend this event?

As a senior industry executive, you will be aware of the importance and potential of this field. This conference offers you the opportunity to discover the potential and realities of oncology research, to match your company’s resources to the needs of drug discovery.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Alan Lewis

Dr Alan Lewis, President, Celgene

9:10 NITRIC OXIDE RELEASING ANTI-INFLAMMATORY DRUGS

Dr Giancarlo Santus

Dr Giancarlo Santus, Vice President, Product Development, NicOx

  • Role of nitric oxide in inflammation
  • Field of application of NO-donor drugs
  • Approaches taken in the development
  • Initial findings from Phase I and II clinical trials
  • Comparison and potential advantages over existing compounds
  • Perspective from an Intellectual Properties point of view
  • 9:40 NO-CYCLOOXYGENASE-2 SELECTIVE INHIBITORS

    Dr Gordon Letts

    Dr Gordon Letts, Chief Scientific Officer & Senior Vice President, Research & Development, NitroMed

  • COX-2 selective inhibitors
  • Nitric oxide
  • In vitro pharmacology profile
  • In vivo comparison of COX-2 selective inhibitors and NO-COX-2 selective inhibitors
  • 10:20 COMPLEMENT INHIBITION AS A THERAPEUTIC APPROACH TO ACUTE AND CHRONIC INFLAMMATION

    Dr Stephen Squinto

    Dr Stephen Squinto, Executive Vice President & Head of Research, Alexion Pharmaceuticals

  • The complement system and inflammation
  • Effective complement blockade in cardiopulmonary bypass patients
  • Complement blockade in rheumatoid arthritis patients
  • Complement blockade in other autoimmune diseases
  • 11:00 Morning Coffee

    11:20 L.E.A.P.S.ä PEPTIDES AS POTENTIAL IMMUNOTHERAPEUTIC AGENTS

    Dr Daniel Zimmerman

    Dr Daniel Zimmerman, Senior Vice President, Research, Cellular Immunology, CEL-SCI Corporation

  • Background to the L.E.A.P.S. technology
  • Overview of immune responses and protection induced using L.E.A.P.S. constructs
  • Relevance of responses obtained in infectious disease models to autoimmune conditions
  • Mechanism of action of L.E.A.P.S. constructs drawn from the above systems, including identification of some cells, cytokines and other molecules involved
  • Advantages and disadvantages of L.E.A.P.S. constructs, including comparison with monoclonal antibodies, soluble receptors and other vaccine technologies
  • Potential sources of autoimmune or other inflammatory diseases with epitopes suitable for L.E.A.P.S. technology

    Next steps for the L.E.A.P.S. technology

  • 12:00 HuMax-CD4 - A CELLULAR ANTI-INFLAMMATORY APPROACH

    Dr Claus Juan Møller-San Pedro

    Dr Claus Juan Møller-San Pedro, Chief Operating Officer, Genmab

  • Blocking of CD4 positive T-cells in inflammatory disease
  • Previous experience with other CD4 antibodies
  • HuMax-CD4 in rheumatoid arthritis
  • HuMax-CD4 in psoriasis
  • Future perspective of CD4 positive T-cell inactivation
  • 12:40 Lunch

    14:00 NEUTRALISATION OF OX40 – A POTENT IMMUNOREGULATORY RECEPTOR

    Dr Herbert Schwarz

    Dr Herbert Schwarz, Director of Cellular Immunology, Xenova Group

  • Immunoregulatory activities of the OX40 receptor / ligand system
  • Mechanisms of amelioration of autoimmune disease by OX40 blockage
  • Rational design of immunoglobulin effector functions in OX40-IgG fusion proteins
  • Pre-clinical in vivo data on OX40-IgG
  • Comparison of OX40-IgG to similar anti-inflammatory therapies
  • 14:40 CASE STUDY – CELGENE

    Dr Alan Lewis

    Dr Alan Lewis, President, Celgene

  • Celgene’s approach to anti-inflammatory therapies
  • The MAP kinase gene regulating pathways and their relation to inflammatory diseases
  • Update on Celgene’s progress in this area
  • The potential of the novel JNK inhibitor for the treatment of Asthma – Results from a preclinical study
  • The advantage of the JNK inhibitor over glucocorticoids and the impact it would make on the Asthma therapeutics’ market
  • Progress on filing an Investigational New Drug application for the JNK inhibitor
  • 15:20 Afternoon Tea

    15:40 SPECTRUM OF DISEASE RELATED TO INFLAMMATORY CYTOKINES

    Dr Terry Plasse

    Dr Terry Plasse, Vice President, Research & Development, Cytokine PharmaSciences

  • Overview of the relationship between inflammatory cytokines and human diseases
  • Preclinical activity of CNI-1493, a synthetic guanylhydrazone
  • Potential mechanisms of action
  • Clinical activity of CNI-1493
  • 16:20 CASE STUDY - ELIDEL® FROM NOVARTIS

    Prof Anton Stütz, PhD

    Prof Anton Stütz, PhD, Head, Inflammatory Skin Diseases, Novartis Research Institute

  • An alternative to treatment with topical corticosteroids
  • A new option for oral treatment
  • Ascomycin Macrolactam, ASM 981, as a selective inflammatory cytokine inhibitor? – the anti-inflammatory mechanism
  • The approach taken in development of this therapy
  • Results from the clinical trials
  • Results of the first therapeutic study in medicine that includes pharmacogenomic analysis

    The impact of this on inflammatory skin disease, the current therapeutic market and the future of treatment

  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Alan Lewis

    Dr Alan Lewis, President, Celgene

    9:10 NEUTRALISATION OF THE TUMOUR NECROSIS FACTOR (TNF) I - ANTIBODY APPROACH

    Dr Roly Foulkes

    Dr Roly Foulkes, Head of Pharmacology and DMPK, Celltech

  • Brief introduction to anti-TNF therapies in inflammatory disease treatment
  • Humanisation of antibodies
  • Increasing the capacity to supply the market through the use of antibody fragments
  • Agreement on development and marketing of CDP 870 with Pharmacia
  • The use of anti-TNF antibodies in treating other inflammatory disorders – results from studies
  • Comparison with NSAID treatments and anti-TNF therapies via the antibody approach
  • 9:40 NEUTRALISATION OF THE TUMOUR NECROSIS FACTOR (TNF) II – SOLUBLE RECEPTOR PROTEIN APPROACH

    Dr Kendall Mohler

    Dr Kendall Mohler, Vice President of Biologic Sciences, Immunex

  • ENBREL® as a competitive inhibitor of TNF molecules binding to TNF receptor (TNFR)
  • The demand for ENBREL® - meeting the needs of current and future users
  • Safety profile of ENBREL®
  • Additional inflammatory indications that benefit from TNF antagonism
  • Identifying additional therapeutic targets for patients that don’t respond to TNF antagonists
  • 10:20 V-PROTECTANTS AS ANTI-INFLAMMATION THERAPEUTICS

    Dr. Martin A. Wasserman

    Dr. Martin A. Wasserman, Vice President of Discovery Research and Chief Scientific Officer, AtheroGenics, Inc.

  • V-protectants (vascular protectants) are small molecule drugs which block oxidant signals and the production of proteins, e.g., VCAM-1, necessary to initiate and perpetuate chronic inflammation.
  • Diseases targeted with the v-protectant technology platform.
  • Preclinical profile with the leading v-protectant, AGI-1067.
  • Results of a Phase II clinical trial (CART-1) with AGI-1067 in the prevention and treatment of post-angioplasty restenosis.
  • 11:00 Morning Coffee

    11:20 CASE STUDY – PLIVA

    Dr Radan Spaventi

    Dr Radan Spaventi, Vice President for Research and Development, PLIVA

  • Strategic approaches
  • Mechanistic studies
  • Indications
  • 12:00 CASE STUDY – PROTEIN DESIGN LABS

    Dr Daniel Levitt

    Dr Daniel Levitt, President, Research and Development, Protein Design Labs

  • Introduction to the potential of antibodies for the treatment of Crohn’s disease
  • How is this approach different to current treatments that are in the pipeline?
  • Overview of results from the Phase I trial
  • Initial findings from Phase II clinical trial with regards to safety, tolerability, pharmacokinetics, pharmacodynamics, human anti-human antibody responses and changes in disease state
  • Assessment of the potential of this as a treatment for Inflammatory Bowel Disease
  • Developments in humanised antibodies for the treatments of other inflammatory conditions
  • 12:40 Lunch

    14:00 THE PROFILE OF SCH351591

    Dr John Montana

    Dr John Montana, Director NCE Research, Celltech

  • Discovery and profile of our first PDE4 inhibitor, D4418
  • The design of compound SCH351591
  • Structure, In vitro potency, selectivity and pharmacokinetic profile
  • In vivo efficacy, in animal models of respiratory disease
  • 14:40 INFLAMMATORY DISEASES OF THE AIRWAYS

    Dr Claude Bertrand

    Dr Claude Bertrand, Director of Allergy and Respiratory Diseases, Pfizer Global R&D

  • The pathophysiology of asthma
  • The pathophysiology of COPD
  • Inflammatory processes in asthma
  • Inflammatory processes in COPD
  • Novel approaches to treat asthma and COPD
  • 15:20 CLINICAL ENDPOINTS IN DRUG DEVELOPMENT FOR OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

    Dr William Sietsema

    Dr William Sietsema, Vice President, Clinical Development, Kendle International

  • Pain Endpoints: VAS, Categorical, McGill, Brief Pain Inventory, Joint Counts
  • Function Endpoints: HAQ, AIMS, WOMAC, OASI
  • Global Endpoints: Patient, Physician, VAS, Categorical
  • Radiographic Measures: X-ray, Magnetic Resonance Imaging, Computerized Tomography, Microfocal Radiography
  • Biological Markers
  • Composite Endpoints: ACR20, DAS, EULAR. OARSI

    Safety and Toxicity Measures: Stanford Toxicity Index, Rheumatology Common Toxicity Criteria Index

  • 16:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.